BRISTOL-MYERS SQUIBB COMPANY Sales Revenue, Goods, Net (Deprecated 2018-01-31)
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Sales Revenue, Goods, Net (Deprecated 2018-01-31) of $5.43 billion for the 3-month period ending 2018-09-30, per its 10-Q filed 2018-10-25.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SalesRevenueGoodsNet · last filed 2018-10-25
- BRISTOL-MYERS SQUIBB COMPANY sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2018-09-30 was $5.43B, a 11.74% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2018-06-30 was $5.46B, a 14.49% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $4.97B, a 8.56% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $5.05B, a 4.82% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2017 was $19.26B, a 8.79% increase from fiscal 2016.
- BRISTOL-MYERS SQUIBB COMPANY sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2016 was $17.70B, a 26.04% increase from fiscal 2015.
- BRISTOL-MYERS SQUIBB COMPANY sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2015 was $14.04B, a 20.45% increase from fiscal 2014.
- BRISTOL-MYERS SQUIBB COMPANY sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2014 was $11.66B, a 5.23% decline from fiscal 2013.
| Period end | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 3 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 6 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 9 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2018-09-30 | $5.43B 10-Q · filed 2018-10-25 | $10.89B derived: sum of 2 quarters · filed 2018-10-25 | $15.87B 10-Q · filed 2018-10-25 | $20.91B derived: sum of 4 quarters · filed 2018-10-25 |
| 2018-06-30 | $5.46B 10-Q · filed 2018-07-26 | $10.43B 10-Q · filed 2018-07-26 | $15.48B derived: sum of 3 quarters · filed 2018-07-26 | $20.34B derived: sum of 4 quarters · filed 2018-10-25 |
| 2018-03-31 | $4.97B 10-Q · filed 2018-04-26 | $10.02B derived: sum of 2 quarters · filed 2018-04-26 | $14.88B derived: sum of 3 quarters · filed 2018-10-25 | $19.65B derived: sum of 4 quarters · filed 2018-10-25 |
| 2017-12-31 | $5.05B derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | $9.91B derived: sum of 2 quarters · filed 2018-10-25 | $14.68B derived: sum of 3 quarters · filed 2018-10-25 | $19.26B 10-K · filed 2018-02-13 |
| 2017-09-30 | $4.86B 10-Q · filed 2018-10-25 | $9.63B derived: sum of 2 quarters · filed 2018-10-25 | $14.21B 10-Q · filed 2018-10-25 | $19.03B derived: sum of 4 quarters · filed 2018-10-25 |
| 2017-06-30 | $4.77B 10-Q · filed 2018-07-26 | $9.35B 10-Q · filed 2018-07-26 | $14.16B derived: sum of 3 quarters · filed 2018-07-26 | $18.66B derived: sum of 4 quarters · filed 2018-07-26 |
| 2017-03-31 | $4.58B 10-Q · filed 2018-04-26 | $9.39B derived: sum of 2 quarters · filed 2018-04-26 | $13.89B derived: sum of 3 quarters · filed 2018-04-26 | $18.32B derived: sum of 4 quarters · filed 2018-04-26 |
| 2016-12-31 | $4.81B derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | $9.31B derived: sum of 2 quarters · filed 2018-02-13 | $13.74B derived: sum of 3 quarters · filed 2018-02-13 | $17.70B 10-K · filed 2018-02-13 |
| 2016-09-30 | $4.49B 10-Q · filed 2017-10-26 | $8.92B derived: sum of 2 quarters · filed 2017-10-26 | $12.89B 10-Q · filed 2017-10-26 | $16.75B derived: sum of 4 quarters · filed 2018-02-13 |
| 2016-06-30 | $4.43B 10-Q · filed 2017-07-27 | $8.40B 10-Q · filed 2017-07-27 | $12.26B derived: sum of 3 quarters · filed 2018-02-13 | $15.81B derived: sum of 4 quarters · filed 2018-02-13 |
| 2016-03-31 | $3.96B 10-Q · filed 2017-04-27 | $7.83B derived: sum of 2 quarters · filed 2018-02-13 | $11.38B derived: sum of 3 quarters · filed 2018-02-13 | $14.95B derived: sum of 4 quarters · filed 2018-02-13 |
| 2015-12-31 | $3.86B derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | $7.41B derived: sum of 2 quarters · filed 2018-02-13 | $10.99B derived: sum of 3 quarters · filed 2018-02-13 | $14.04B 10-K · filed 2018-02-13 |
| 2015-09-30 | $3.55B 10-Q · filed 2016-10-27 | $7.12B derived: sum of 2 quarters · filed 2016-10-27 | $10.18B 10-Q · filed 2016-10-27 | $13.42B derived: sum of 4 quarters · filed 2017-02-21 |
| 2015-06-30 | $3.57B 10-Q · filed 2016-07-28 | $6.63B 10-Q · filed 2016-07-28 | $9.87B derived: sum of 3 quarters · filed 2017-02-21 | $12.71B derived: sum of 4 quarters · filed 2017-02-21 |
| 2015-03-31 | $3.06B 10-Q · filed 2016-04-28 | $6.30B derived: sum of 2 quarters · filed 2017-02-21 | $9.14B derived: sum of 3 quarters · filed 2017-02-21 | $11.91B derived: sum of 4 quarters · filed 2017-02-21 |
| 2014-12-31 | $3.24B derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-21 | $6.08B derived: sum of 2 quarters · filed 2017-02-21 | $8.85B derived: sum of 3 quarters · filed 2017-02-21 | $11.66B 10-K · filed 2017-02-21 |
| 2014-09-30 | $2.84B 10-Q · filed 2015-10-27 | $5.61B derived: sum of 2 quarters · filed 2015-10-27 | $8.42B 10-Q · filed 2015-10-27 | $11.72B derived: sum of 4 quarters · filed 2016-02-12 |
| 2014-06-30 | $2.77B 10-Q · filed 2015-07-23 | $5.58B 10-Q · filed 2015-07-23 | $8.88B derived: sum of 3 quarters · filed 2016-02-12 | $11.90B derived: sum of 4 quarters · filed 2016-02-12 |
| 2014-03-31 | $2.81B 10-Q · filed 2015-04-28 | $6.11B derived: sum of 2 quarters · filed 2016-02-12 | $9.13B derived: sum of 3 quarters · filed 2016-02-12 | $12.15B derived: sum of 4 quarters · filed 2016-02-12 |
| 2013-12-31 | $3.30B derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-12 | $6.32B derived: sum of 2 quarters · filed 2016-02-12 | $9.35B derived: sum of 3 quarters · filed 2016-02-12 | $12.30B 10-K · filed 2016-02-12 |
| 2013-09-30 | $3.02B 10-Q · filed 2014-10-24 | $6.05B derived: sum of 2 quarters · filed 2014-10-24 | $9.01B 10-Q · filed 2014-10-24 | |
| 2013-06-30 | $3.02B 10-Q · filed 2014-07-24 | $5.98B 10-Q · filed 2014-07-24 | ||
| 2013-03-31 | $2.96B 10-Q · filed 2014-04-29 | |||
| 2012-12-31 | $13.65B 10-K · filed 2015-02-13 | |||
| 2011-12-31 | $17.62B 10-K · filed 2014-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |